A successful Mylan challenge would see generic entry within two years – though Biogen has fought off copycats before.
Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.
Celgene stock falls 9%, suggesting that an activist campaign to derail its takeover by Bristol-Myers Squibb is reaching critical mass.
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
Of the five biggest products set to lose exclusivity in the US this year the Swiss pharma giant owns three: Avastin, Herceptin and Tarceva.
Abbvie's latest move to shore up Humira sales against a biosimilar onslaught involves politically sensitive price hikes.
Pain drugs look like they could face different outcomes, while targeted cancer agents will have a big month. Two biosimilar decisions also await.
Higher-risk novel drug development is chosen over lower-cost volume play as US biosimilar growth continues to sputter.
A non-profit partnership of 500 hospitals wants to deliver its first generic drugs in 2019, lowering prices and stabilising supplies.